A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Recruiting

Phase 3

Obicetrapib & EzetimibeA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Sponsor:

NewAmsterdam Pharma

Code:

NCT07219602

Conditions

Lipidemia

Type 2 Diabetes (T2DM)

Metabolic Syndrome (MetS)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

obicetrapib 10 mg + ezetimibe 10 mg FDC daily

Obicetrapib 10 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-06. This information was provided to ClinicalTrials.gov by NewAmsterdam Pharma on 2026-03-10.